381 related articles for article (PubMed ID: 25080475)
1. A nontumorigenic variant of FGF19 treats cholestatic liver diseases.
Luo J; Ko B; Elliott M; Zhou M; Lindhout DA; Phung V; To C; Learned RM; Tian H; DePaoli AM; Ling L
Sci Transl Med; 2014 Jul; 6(247):247ra100. PubMed ID: 25080475
[TBL] [Abstract][Full Text] [Related]
2. Liver: a variant of FGF19 protects the liver from cholestatic injury without inducing cancer.
Patman G
Nat Rev Gastroenterol Hepatol; 2014 Oct; 11(10):579. PubMed ID: 25134510
[No Abstract] [Full Text] [Related]
3. Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2-deficient mice.
Zhou M; Learned RM; Rossi SJ; DePaoli AM; Tian H; Ling L
Hepatology; 2016 Mar; 63(3):914-29. PubMed ID: 26418580
[TBL] [Abstract][Full Text] [Related]
4. High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis.
Schaap FG; van der Gaag NA; Gouma DJ; Jansen PL
Hepatology; 2009 Apr; 49(4):1228-35. PubMed ID: 19185005
[TBL] [Abstract][Full Text] [Related]
5. Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial.
Hirschfield GM; Chazouillères O; Drenth JP; Thorburn D; Harrison SA; Landis CS; Mayo MJ; Muir AJ; Trotter JF; Leeming DJ; Karsdal MA; Jaros MJ; Ling L; Kim KH; Rossi SJ; Somaratne RM; DePaoli AM; Beuers U
J Hepatol; 2019 Mar; 70(3):483-493. PubMed ID: 30414864
[TBL] [Abstract][Full Text] [Related]
6. Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19.
Zhou M; Wang X; Phung V; Lindhout DA; Mondal K; Hsu JY; Yang H; Humphrey M; Ding X; Arora T; Learned RM; DePaoli AM; Tian H; Ling L
Cancer Res; 2014 Jun; 74(12):3306-16. PubMed ID: 24728076
[TBL] [Abstract][Full Text] [Related]
7. An FXR Agonist Reduces Bile Acid Synthesis Independently of Increases in FGF19 in Healthy Volunteers.
Al-Khaifi A; Rudling M; Angelin B
Gastroenterology; 2018 Oct; 155(4):1012-1016. PubMed ID: 29928896
[TBL] [Abstract][Full Text] [Related]
8. Developmental regulation of the gut-liver (FGF19-CYP7A1) axis in neonates.
Memon N; Griffin IJ; Lee CW; Herdt A; Weinberger BI; Hegyi T; Carayannopoulos MO; Aleksunes LM; Guo GL
J Matern Fetal Neonatal Med; 2020 Mar; 33(6):987-992. PubMed ID: 30122083
[No Abstract] [Full Text] [Related]
9. Alisol B 23-acetate protects against ANIT-induced hepatotoxity and cholestasis, due to FXR-mediated regulation of transporters and enzymes involved in bile acid homeostasis.
Meng Q; Chen XL; Wang CY; Liu Q; Sun HJ; Sun PY; Huo XK; Liu ZH; Yao JH; Liu KX
Toxicol Appl Pharmacol; 2015 Mar; 283(3):178-86. PubMed ID: 25655198
[TBL] [Abstract][Full Text] [Related]
10. Nuclear receptor FXR, bile acids and liver damage: Introducing the progressive familial intrahepatic cholestasis with FXR mutations.
Cariello M; Piccinin E; Garcia-Irigoyen O; Sabbà C; Moschetta A
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1308-1318. PubMed ID: 28965883
[TBL] [Abstract][Full Text] [Related]
11. A GAPDH-mediated trans-nitrosylation pathway is required for feedback inhibition of bile salt synthesis in rat liver.
Rodríguez-Ortigosa CM; Celay J; Olivas I; Juanarena N; Arcelus S; Uriarte I; Marín JJ; Avila MA; Medina JF; Prieto J
Gastroenterology; 2014 Nov; 147(5):1084-93. PubMed ID: 25066374
[TBL] [Abstract][Full Text] [Related]
12. The effect of colesevelam treatment on bile acid and lipid metabolism and glycemic control in healthy men.
Blahová T; Peterková L; Leníček M; Vlachová M; Zemánková K; Adámková V; Vítek L; Kovář J
Physiol Res; 2016 Dec; 65(6):995-1003. PubMed ID: 27539104
[TBL] [Abstract][Full Text] [Related]
13. Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man.
Lundåsen T; Gälman C; Angelin B; Rudling M
J Intern Med; 2006 Dec; 260(6):530-6. PubMed ID: 17116003
[TBL] [Abstract][Full Text] [Related]
14. The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance.
Schreuder TC; Marsman HA; Lenicek M; van Werven JR; Nederveen AJ; Jansen PL; Schaap FG
Am J Physiol Gastrointest Liver Physiol; 2010 Mar; 298(3):G440-5. PubMed ID: 20093562
[TBL] [Abstract][Full Text] [Related]
15. Synergistic role of 3-hydroxy-3-methylglutaryl coenzyme A reductase and cholesterol 7alpha-hydroxylase in the pathogenesis of manganese-bilirubin-induced cholestasis in rats.
Akoume MY; Perwaiz S; Yousef IM; Plaa GL
Toxicol Sci; 2003 Jun; 73(2):378-85. PubMed ID: 12700418
[TBL] [Abstract][Full Text] [Related]
16. Engineered FGF19
Shi L; Zhao T; Huang L; Pan X; Wu T; Feng X; Chen T; Wu J; Niu J
BMC Biotechnol; 2023 Oct; 23(1):43. PubMed ID: 37789318
[TBL] [Abstract][Full Text] [Related]
17. The gut-liver axis in hepatocarcinoma: a focus on the nuclear receptor FXR and the enterokine FGF19.
Piglionica M; Cariello M; Moschetta A
Curr Opin Pharmacol; 2018 Dec; 43():93-98. PubMed ID: 30223181
[TBL] [Abstract][Full Text] [Related]
18. Suppression of bile acid synthesis, but not of hepatic cholesterol 7alpha-hydroxylase expression, by obstructive cholestasis in humans.
Bertolotti M; Carulli L; Concari M; Martella P; Loria P; Tagliafico E; Ferrari S; Del Puppo M; Amati B; De Fabiani E; Crestani M; Amorotti C; Manenti A; Carubbi F; Pinetti A; Carulli N
Hepatology; 2001 Aug; 34(2):234-42. PubMed ID: 11481606
[TBL] [Abstract][Full Text] [Related]
19. Regulation of bile acid metabolism in biliary atresia: reduction of FGF19 by Kasai portoenterostomy and possible relation to early outcome.
Johansson H; Svensson JF; Almström M; Van Hul N; Rudling M; Angelin B; Nowak G; Fischler B; Ellis E
J Intern Med; 2020 May; 287(5):534-545. PubMed ID: 31976601
[TBL] [Abstract][Full Text] [Related]
20. [Cholestatic liver diseases].
Reichel C; Meier-Abt PJ
Ther Umsch; 1997 Nov; 54(11):639-44. PubMed ID: 9454366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
